Gastrointestinal Stents Market Report

Global Gastrointestinal Stents Market Size

The global gastrointestinal stents market size was valued at USD 573.5 million in 2025 and is estimated to reach USD 931.72 million by 2034 from USD 605.27 million in 2026, registering a CAGR of 5.54% from 2026 to 2034.

MARKET DRIVERS

The growing incidence of gastrointestinal disorders such as gastrointestinal malignancies, strictures, and inflammatory bowel disease majorly drives the growth of the gastrointestinal stents market. According to the World Gastroenterology Organisation, approximately 8% of all cancer fatalities worldwide are attributable to gastrointestinal cancers. Similarly, the American Gastroenterological Association estimates that approximately 3 million Americans suffer from inflammatory bowel disease. This increasing prevalence of gastrointestinal disorders drives demand for stenting procedures to improve patient outcomes.

The growing adoption of minimally invasive surgical procedures further propels the growth of the gastrointestinal stents market. These procedures, which are typically performed using endoscopic techniques, offer alternatives to open surgical procedures that are less invasive. They are linked to fewer complications, shorter hospital stays, and quicker recovery periods. The growing aging population worldwide drives the demand for gastrointestinal stents and boosts the market growth. According to the United Nations, the worldwide population of people aged 60 and more will reach 2.1 billion by 2050. This demographic shift is linked to an increase in the prevalence of gastrointestinal disorders requiring stenting. According to the American Cancer Society, more than 90% of colorectal cancer diagnoses occur in those aged 50 and up.

Technological advancements promote the gastrointestinal stents market growth. Self-expandable metallic stents (SEMS) and biodegradable stents have increased in efficacy and safety. Research studies back up their usefulness, such as one published in the Journal of Gastrointestinal Surgery that revealed a 92% technical success rate in treating malignant colorectal blockages with SEMS. The growing awareness and implementing screening programmes have played an important role in recognising gastrointestinal problems early and raising the demand for stenting procedures. For example, in the United Kingdom, the National Health Service developed the "Bowel Cancer Screening Programme," which resulted in a considerable increase in the detection and treatment of early-stage colorectal malignancies. Favourable reimbursement policies and growing support from the governmental organizations have also aided in the adoption of gastrointestinal stents and contributes to the market growth. For example, the Centres for Medicare and Medicaid Services (CMS) reimburses endoscopic stenting operations for certain indications in the United States.

MARKET RESTRAINTS

High costs associated with gastrointestinal stenting is one of the key factors hampering the market growth. Pre- and post-operative care, imaging and follow-up visits may incur additional charges. These fees can be financially burdensome for patients, especially in areas with limited healthcare coverage or insurance options. The risk of complications from gastrointestinal stenting procedures further impedes the market growth. While stenting is typically considered a safe and successful treatment option, problems such as stent migration, fracture, tissue overgrowth, and perforation can occur. These consequences can lead to additional interventions, raising healthcare expenses and causing discomfort to patients. Stringent laws and compliance requirements hinder the market growth.

REPORT COVERAGE

SEGMENTAL ANALYSIS 

By Product Type Insights

Based on product type, the self-expandable metallic stents (SEMS) segment currently dominates the market and is expected to occupy the leading share of the global market during the forecast period. A research study published in the Journal of Gastrointestinal Surgery found that using SEMS to treat malignant colorectal blockages had a 92% technical success rate. SEMS benefits include ease of deployment, high radial strength, and longevity. They're commonly utilised to treat gastrointestinal strictures and malignant obstructions. Factors such as the growing demand for self-expandable metallic stents due to their effectiveness in treating various gastrointestinal conditions, increasing usage of self-expandable metallic stents and continuous advancements in design and material composition primarily drive the growth of the SEMS in the worldwide market. The growing preference for minimally invasive procedures and increasing incidence of gastrointestinal diseases and disorders further boost the growth rate of the SEMS segment in the global market.

The biodegradable stents segment is predicted to grow the fastest CAGR during the forecast period. Growing interest in biodegradable solutions for temporary stenting, increasing usage of biodegradable stents in specific gastrointestinal conditions and post-surgical interventions, advancements in biodegradable stent design and degradation kinetics and increasing demand for minimally invasive and non-permanent treatment options majorly drive the growth of the biodegradable stents in the worldwide market.

By Application Insights

Based on application, the colorectal cancer segment is expected to capture the major share of the global market during the forecast period. Colorectal cancer is one of the most common indications for stent placement and the global increase in colorectal cancer incidence contributes to the growth of colorectal cancer segment in the global market. According to the American Cancer Society 2020, the lifetime likelihood of acquiring colorectal cancer is approximately 1 in 22, or 4.49% for men and 1 in 24, or 4.15% for women.  The growing number of advancements in stent technology for effective tumor palliation and symptom relief, rising emphasis on early detection and screening programs, growing aging population and lifestyle factors and increasing number of improvements in endoscopic techniques and stent deployment methods further boost the growth rate of the colorectal cancer segment in the worldwide market.

However, the esophageal cancer segment is expected to grow at the highest CAGR in the coming years. Esophageal cancer often presents with dysphagia and requires stenting to relieve symptoms and improve the quality of life for patients. Technological advancements in esophageal stent design for improved patient outcomes, rapid adoption of minimally invasive procedures for esophageal cancer treatment and advances in imaging modalities aiding in the early detection and staging of esophageal cancer drive the growth of the esophageal cancer segment in the worldwide market.

REGIONAL ANALYSIS

North America currently dominates the worldwide gastrointestinal stents market and Is anticipated to continue the domination in the worldwide market throughout the forecast period. The availability of a well-developed healthcare infrastructure, cutting-edge medical technologies and a high prevalence of gastrointestinal diseases primarily contributes to the growth of the North American market. According to the Centres for Disease Control and Prevention, the number of adults diagnosed with ulcers in the United States was 14.8 million, and the number of visits to emergency departments for disorders of the digestive system as the primary diagnosis was 7.9 million in the year 2020. Favorable reimbursement policies and insurance coverage for gastrointestinal stent procedures, the presence of key market players and research institutions, strong emphasis on patient safety and quality of care in healthcare systems and growing awareness and education programs on gastrointestinal diseases and available treatment options further boost the growth rate of the North American market. The U.S. led the market in the North American market, followed by Canada.

Europe is expected to capture a substantial share of the global market during the forecast period owing to the presence of a stringent regulatory standards and adherence to patient safety and efficacy requirements. The presence of a well-developed healthcare infrastructure and access to advanced diagnostic and therapeutic procedures and increasing number of government initiatives promoting early detection and treatment of gastrointestinal diseases contributes to the European market. Collaborations between healthcare organizations and industry players for research and development of innovative stent solutions, rising focus on personalized medicine and precision therapies in gastroenterology and growing investments in clinical trials and research studies related to gastrointestinal stents further promotes the European market. The UK dominated the market in Europe, followed by Germany in 2022.

APAC is the most lucrative regional market for gastrointestinal stents and is estimated to witness the highest CAGR among all the regions during the forecast period. The rapidly growing incidence of esophageal and gastric cancers in countries like China, Japan, and South Korea, growing healthcare spending and investments in advanced medical technologies propel the APAC market growth. Rapid adoption of telemedicine and digital health platforms, rising awareness among healthcare professionals and patients about the benefits of stent placement for gastrointestinal conditions and increasing focus on developing cost-effective stent solutions tailored to the specific needs of the Asian population further support the growth of the APAC market. China, Japan, India and South Korea are predicted to hold the major share of the APAC market during the forecast period.

KEY MARKET PLAYERS

Some of the companies that are playing a dominating role in the global gastrointestinal stents market include

• Boston Scientific Corporation
• Cook Medical LLC
• Medtronic plc
• Olympus Corporation
• C.R. Bard, Inc.
• Taewoong Medical Co., Ltd.
• Micro-Tech (Nanjing) Co., Ltd.
• ELLA-CS, s.r.o.
• Merit Medical Systems, Inc.
• ConMed Corporation

MARKET SEGMENTATION

This research report on the global gastrointestinal stents market has been segmented and sub-segmented based on the following categories.

By Product Type

• Self-Expandable Metallic Stents (SEMS)
• Self-Expandable Plastic Stents (SEPS)
• Biodegradable Stents
• Covered Stents
• Drug-Eluting Stents
• Others

By Application

• Colorectal Cancer
• Esophageal Cancer
• Biliary Diseases
• Pancreatic Diseases
• Inflammatory Bowel Disease
• Others

By Region

• North America

• Europe
• Asia Pacific
• Latin America
• Middle East & Africa